Letermovir: all 39 studies that test it

Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Letermovir for R+ StudyNot yet recruitingNCT07706166Phase 4
• Letermovir vs Valganciclovir in CMV R+ Kidney TransplantNot yet recruitingNCT07571135Phase 4
• Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisRecruitingNCT07488728Not applicable
• Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant RecipientsRecruitingNCT07235683Phase 4
• A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)RecruitingNCT07199465Phase 1
• Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without HaemodialysisNot yet recruitingNCT07101055Phase 1
• Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart TransplantRecruitingNCT07079735Phase 2/3
• Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapyRecruitingNCT06920251Phase 2
• The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant RecipientsRecruitingNCT06639854Not applicable
• Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 InfectionNot yet recruitingNCT06626555Phase 2
• Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T CellRecruitingNCT06575374Phase 2
• CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCTRecruitingNCT06453460Phase 2
• Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant RecipientsRecruitingNCT06407232Phase 3
• Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus InfectionNot yet recruitingNCT06341686Phase 3
• Letermovir-based Dual Therapy for Treatment of Cytomegalovirus InfectionsRecruitingNCT06334497Phase 3
• Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.Not yet recruitingNCT06057194Phase 2
• Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host DiseaseNot yet recruitingNCT05969743Phase 2
• Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCTNot yet recruitingNCT05914675Phase 4
• A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsRecruitingNCT05711667Phase 3
• Letermovir for Secondary Prophylaxis in Solid Organ Transplant RecipientsRecruitingNCT05626530Phase 4
• Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus ValaciclovirRecruitingNCT05446571Phase 3
• A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)CompletedNCT05763823Phase 3Results posted
• Letermovir for CMV Prevention After Lung TransplantationCompletedNCT05041426Phase 2Results posted
• Letermovir Use in Heart Transplant RecipientsCompletedNCT04904614Phase 4Results posted
• A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.TerminatedNCT04840199Phase 2Results posted
• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
• MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)CompletedNCT04129398Phase 3Results posted
• Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)CompletedNCT03940586Phase 2Results posted
• Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)CompletedNCT03930615Phase 3Results posted
• Letermovir Treatment for Refractory or Resistant Cytomegalovirus InfectionCompletedNCT03728426Phase 2Results posted
• Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)CompletedNCT03443869Phase 3Results posted
• Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)CompletedNCT02137772Phase 3Results posted
• Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted PatientsCompletedNCT01063829Phase 2Results posted
• CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCTActive, not recruitingNCT06449586Phase 3
• A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital CytomegalovirusCompletedNCT06118515Phase 1
• Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsActive, not recruitingNCT06066957Phase 2
• De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant RecipientsCompletedNCT06001320Phase 3
• Letermovir in ART-treated HIV-infected PersonsCompletedNCT05362916Not applicable
• Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1CompletedNCT04732260Not applicable

← Letermovir overview